SCHEMBL24724941

SCHEMBL24724941

CC(C)CN1CCN(c2ccc(C(=O)C(C)C)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
OGA O60502 3/20 0.42
ALDH1A1 P00352 2/20 0.42
RET P07949 1/20 0.41
MAPT P10636 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR7 P34969 1/20 0.41
DRD3 P35462 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9205961 0.85 KMT2A (0.64) KMT2ANPC1RAB9AOGAMAPT
SCHEMBL25719319 0.84 RAB9A (0.47) KMT2ANPC1RAB9AOPRM1OPRK1
SCHEMBL19845916 0.83 UBE2T (0.53) KMT2ANPC1RAB9AOPRM1OPRK1
SCHEMBL25703965 0.82 UBE2T (0.46) KMT2ANPC1RAB9AOPRM1OPRK1
SCHEMBL24725715 0.81 ALDH1A1 (0.47) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL25667152 0.80 ALDH1A1 (0.66) KMT2ANPC1RAB9AALDH1A1MAPT
SCHEMBL24725714 0.79 KMT2A (0.51) KMT2AALDH1A1MAPTHTR7DRD3
SCHEMBL19598470 0.79 HRH3 (0.43) KMT2ANPC1RAB9AOGAHTR1A
SCHEMBL7540818 0.77 SCD (0.49) NPC1RAB9AALDH1A1MAPTNPSR1
SCHEMBL7543520 0.77 SCD (0.49) NPC1RAB9AALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023009554-A1 METHODS TO REDUCE ADVERSE EFFECTS OF GENE OR BIOLOGICS THERAPY AVILAR THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
WO-2022235699-A2 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed